References
- Coyne KS, Sexton CC, Vats V, et al. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology 2011;77:1081–7
- Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003;61:37–49
- Shah S, Nitti VW. Defining efficacy in the treatment of overactive bladder syndrome. Rev Urol 2009;11:196–202
- Ganz ML, Smalarz AM, Krupski TL, et al. Economic costs of overactive bladder in the United States. Urology 2010;75:526–32
- Coyne KS, Wein A, Nicholson S, et al. Economic burden of urgency urinary incontinence in the United States: a systematic review. J Manag Care Pharm 2014;20:130–40
- American Urological Association (AUA). Diagnosis and treatment of overactive bladder (non-neurogenic) in adults. AUA/SUFU guideline. Linthicum, MD: American Urological Association, May 2014. Available at: https://www.auanet.org/common/pdf/education/clinical-guidance/Overactive-Bladder.pdf. Accessed July 10, 2014
- Benner JS, Nichol MB, Rovner ES, et al. Patient reported reasons for discontinuing overactive bladder medication. BJU Int 2010;105:1276–82
- D’Souza AO, Smith MJ, Miller LA, et al. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. J Manag Care Pharm 2008;14:291–301
- Schabert VF, Bavendam T, Goldberg EL, et al. Challenges for managing overactive bladder and guidance for patient support. Am J Manag Care 2009;15(4 Suppl):S118–22
- Shaya FT, Blume S, Gu A, et al. Persistence with overactive bladder pharmacotherapy in a Medicaid population. Am J Manag Care 2005;11(4 Suppl):S121–9
- Chancellor MB, Migliaccio-Walle K, Bramley TJ, et al. Long-term patterns of use and treatment failure with anticholinergic agents for overactive bladder. Clin Ther 2013;35:1744–51
- Veenboer PW, Bosch JL. Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review. J Urol 2014;191:1003-8
- Wagg A, Compion G, Fahey A, et al. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int 2012;110:1767–74
- Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–83
- Romano PS, Roos LL, Jollis J. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data. J Clin Epidemiol 1993;46:1075–9.
- Gopal M, Haynes K, Bellamy SL, et al. Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms. Obstet Gynecol 2008;112:1311–18
- Siddiqui E, Anderson P, Jackson J, et al. Comparison of overactive bladder patients who switch between antimuscarinic therapies with those who persist on the same therapy in the absence of improved outcomes: results of a cross-sectional study in 4 European countries. Poster presented at 42nd Annual Meeting of the International Continence Society, Beijing, China, October 15–19, 2012
- Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464–70
- Herschorn SL, Stothers L, Carlson K, et al. Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial. J Urol 2010;183:1892–8